Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Overview

• Investors pushed Summit up 15.44% to $17.94 as the company nears an early second‑quarter look at ivonescimab, a bispecific antibody for lung cancer.
• The HARMONi 3 squamous cohort plans an early Q2 efficacy analysis with final progression‑free survival readout targeted in the second half of 2026.
• Enrollment for the non‑squamous cohort is ongoing, with completion targeted in the second half of 2026 and final progression‑free survival expected in the first half of 2027.
• A separate Phase 3 trial tests ivonescimab plus ligufalimab, an anti‑CD47 antibody, against pembrolizumab monotherapy, using overall survival as the main outcome.
• The FDA is reviewing a biologics license application for ivonescimab plus chemotherapy in EGFR‑mutated non‑squamous lung cancer after EGFR TKI therapy, with a PDUFA decision date of November 14, 2026.